{
    "ticker": "CRDL",
    "name": "Cardiol Therapeutics Inc.",
    "description": "Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on advancing innovative therapies for the treatment of cardiovascular diseases. Founded in 2016 and headquartered in Burlington, Ontario, Canada, Cardiol is dedicated to improving patient outcomes through the development of novel drug formulations and advanced delivery systems. The company's lead product candidate, CardiolRx, is a pharmaceutical formulation of cannabidiol, which is being developed for the treatment of heart disease and inflammation. CardiolRx has shown promise in preclinical studies and is currently undergoing clinical trials to assess its efficacy and safety in patients with refractory angina and heart failure. The company is also exploring additional indications for its products, including inflammatory diseases and conditions related to the cardiovascular system. Cardiol Therapeutics is committed to leveraging cutting-edge research and technology to bring new therapies to market, with the goal of addressing significant unmet medical needs in the cardiovascular space. With a robust pipeline and a focus on scientific innovation, Cardiol aims to become a leader in the development of next-generation cardiovascular therapeutics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Burlington, Ontario, Canada",
    "founded": "2016",
    "website": "https://www.cardioltherapeutics.com",
    "ceo": "Dr. David Elsley",
    "social_media": {
        "twitter": "https://twitter.com/CardiolThera",
        "linkedin": "https://www.linkedin.com/company/cardiol-therapeutics/"
    },
    "investor_relations": "https://www.cardioltherapeutics.com/investors",
    "key_executives": [
        {
            "name": "Dr. David Elsley",
            "position": "CEO"
        },
        {
            "name": "Michael D. W. B. D. Glover",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CardiolRx"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cardiol Therapeutics Inc. | Innovative Cardiovascular Therapies",
        "meta_description": "Explore Cardiol Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapeutics for cardiovascular diseases.",
        "keywords": [
            "Cardiol Therapeutics",
            "CardiolRx",
            "Cardiovascular Disease",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Cardiol Therapeutics known for?",
            "answer": "Cardiol Therapeutics is known for developing innovative therapies for cardiovascular diseases, particularly its lead product CardiolRx."
        },
        {
            "question": "Who is the CEO of Cardiol Therapeutics?",
            "answer": "Dr. David Elsley is the CEO of Cardiol Therapeutics Inc."
        },
        {
            "question": "Where is Cardiol Therapeutics headquartered?",
            "answer": "Cardiol Therapeutics is headquartered in Burlington, Ontario, Canada."
        },
        {
            "question": "What is CardiolRx?",
            "answer": "CardiolRx is a pharmaceutical formulation of cannabidiol being developed for the treatment of heart disease and inflammation."
        },
        {
            "question": "When was Cardiol Therapeutics founded?",
            "answer": "Cardiol Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "CVAC",
        "RGEN",
        "MDGL",
        "VYGR"
    ],
    "related_stocks": [
        "ABT",
        "PFE",
        "MRNA",
        "JNJ"
    ]
}